Live tape
Top 8, mentions 7d183GOOGL30 mentions+0.01INTC29 mentions▲ +0.16NVDA27 mentions▲ +0.08SPY22 mentions+0.00VOO20 mentions▲ +0.04NKE19 mentions-0.01RBA19 mentions▲ +0.05MSFT17 mentions▲ +0.05

Equity · Healthcare

IDXX

IDEXX Laboratories, Inc. · NasdaqGS

$511 +0.79% 1D Finazon · prior-day close · Sep 18, 2026
Price · Chart
Our own end-of-day closes 61 sessions
$600 $500 24 Jun 18 Sep

The line runs $549.15 on 24 June through $511 on 18 September, on a scale from $500 to $600. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of IDXX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $549.15 on 24 June 2026 through $511 on 18 September 2026.

Market cap $40.3B
P/E (TTM) 34.6
52-week range $505 – $766.67
Avg volume 43.1K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 21, 2026

IDXX insider trades

SEC Form 4 · last 90 days · newest reported trade 4 Sep 2026
Open-market buys 0
Open-market sells 1
Net sold $1.17M
Non-trade filings 4
Date Insider Type Shares Value
04 Sep 2026 Kingsley Lawrence D Director Sell 2,203 $1.17M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
04 Sep 2026 Kingsley Lawrence D Director Option exercise 2,203 $252K
20 Aug 2026 Emerson Andrew EVP, CFO and Treasurer Option exercise 265 $47K
20 Aug 2026 Emerson Andrew EVP, CFO and Treasurer Tax withheld 86
30 Jul 2026 HOOLEY JOSEPH L Director Award 49 $27K

IDXX reported financials

SEC EDGAR XBRL

IDXX reported revenue of $4.3B for the fiscal year ended 31 Dec 2025. Net income over the same period was $1.1B.

Figure Reported Period
Revenue $4.3B 31 Dec 2025 fiscal year
Net income $1.1B 31 Dec 2025 fiscal year
Diluted EPS $13.08 31 Dec 2025 fiscal year
Total assets $3.4B 30 Jun 2026 at period end
Total equity $1.6B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

IDXX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $4.27 $1.22B
31 Mar 2026 Q1 2026 $3.47 $1.14B
31 Dec 2025 FY 2025 $13.08 $4.30B
30 Sep 2025 Q3 2025 $3.40 $1.11B
30 Jun 2025 Q2 2025 $3.63 $1.11B
31 Mar 2025 Q1 2025 $2.96 $998M
31 Dec 2024 FY 2024 $10.67 $3.90B
30 Sep 2024 Q3 2024 $2.80 $976M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

IDXX institutional holders

SEC Form 13F

11 of the 45 institutional funds we track reported a IDXX position for the quarter ended 30 Jun 2026 — a combined $930.7M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Fundsmith Trimmed −30.4% shares 1,019,887 $536.9M
Point72 Asset Management Added +103.4% shares 262,905 $138.4M
Renaissance Technologies Added +126.3% shares 109,784 $57.8M
Marshall Wace Added +88.9% shares 93,128 $49.0M
Millennium Management Held (±25%) +12.1% shares 78,980 $41.6M
AQR Capital Management Held (±25%) −20.2% shares 77,198 $40.4M
Man Group Added +48.8% shares 51,382 $27.0M
Citadel Advisors Trimmed −55.6% shares 38,846 $20.5M
Bridgewater Associates Added +225.1% shares 33,528 $17.7M
Balyasny Asset Management Added +38.2% shares 1,808 $952K

Showing the 10 largest of 11 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

IDXX fails-to-deliver

SEC CNS data

On 28 Aug 2026, 47 shares of IDXX failed to deliver (about $26K).

Settlement date Shares failed Notional % of shares out
28 Aug 2026 47 $26K <0.001%
20 Aug 2026 3 $2K <0.001%

Source: SEC fails-to-deliver (CNS) data